Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - pseudoephedrine hydrochloride, quantity: 120 mg; fexofenadine hydrochloride, quantity: 60 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; pregelatinised maize starch; carnauba wax; colloidal anhydrous silica; stearic acid; macrogol 8000; hypromellose; macrogol 400 - for the relief of the symptoms of seasonal allergic rhinitis with nasal congestion when both the antiallergic properties of fexofenadine hydrochloride and the decongestant activity of pseudoephedrine hydrochloride are required.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with narrow-angle glaucoma or urinary retentio

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 60 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate - fast temporary relief from a runny nose and reduce the swollen membranes of the nose and sinuses and helping breathe freely.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: xanthan gum; butyl hydroxybenzoate; propyl hydroxybenzoate; titanium dioxide; disodium edetate; purified water; monobasic sodium phosphate monohydrate; poloxamer; xylitol; propylene glycol; dibasic sodium phosphate heptahydrate; sucrose; flavour - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age. relief of symptoms associated with urticaria in adults and children from 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; hypromellose; povidone; pregelatinised maize starch; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; iron oxide yellow; iron oxide red - relief of symptoms associated with allergic rhinitis in adults and children aged 12 years and older.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with narrow-angle glaucoma or urin

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 60 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate - fast, temporary relief from a runny nose and reduce the swollen membranes of the nose and sinuses and helping breathe easier.

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories limited - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion.  fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology ). fexofenadine hcl 180 mg and pseudoephedrine hcl 240 mg extended-release tablets (24 hour formulation) are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hcl 180 mg and pseudoephedrine hcl  240 mg extended-release tablets (24 hour formulation) are contrai

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 30 mg - tablet, film coated - excipient ingredients: titanium dioxide; pregelatinised maize starch; hypromellose; macrogol 400; colloidal anhydrous silica; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; iron oxide red; iron oxide yellow - relief of symptoms associated with seasonal allergic rhinitis, allergic rhinitis or urticaria in adults and children from 6 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 120 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red - relief of symptoms associated with seasonal allergic rhinitis for adults and children aged 12 years and over.